UroToday1d
ASTRO 2024: Role of Surgery in the Management of Genitourinary Small Cell Tumors
(UroToday.com) The 2024 ASTRO annual meeting included a session on the management of small-cell neuroendocrine tumors of the genitourinary tract, featuring a presentation by Dr. Nima Almassi ...
UroToday1d
IBCN 2024: Investigating BCG Induced B Cell Responses in Patients with Non-Muscle Invasive Bladder Cancer
(UroToday.com) The 2024 IBCN annual meeting included a session on advancements in circulating biomarkers, featuring a presentation by Dr. Priyanka Yolmo discussing BCG-induced B cell responses in ...
UroToday1d
AUA 2024: The Impact of Delayed Administration of Androgen-Receptor Signaling Inhibitors (ARSI) on Prognosis for mHSPC
(UroToday.com) The 2024 American Urological Association (AUA) annual meeting held in San Antonio, TX was host to the advanced prostate cancer moderated poster session. Dr. Ryuma Tanaka presented the ...
UroToday1d
AUA 2024: PSMA-PET Guided Metastasis Directed Therapy for Oligometastatic Prostate Cancer
(UroToday.com) The 2024 American Urological Association (AUA) Annual Meeting held in San Antonio, TX between May 3 rd and 6 th, 2024 was host to an advanced prostate cancer moderated poster session.
UroToday1d
ASTRO 2021: Performance of a Genomic Classifier Within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy After Radical Prostatectomy
(UroToday.com) The 2021 American Society for Radiation Oncology (ASTRO) Hybrid Annual Meeting’s included a session on biomarkers and salvage radiotherapy and discussion by Dr. Alan Dal Pra regarding ...
UroToday1d
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
Bladder cancer is a highly recurrent disease with few treatment options available to patients,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “This program reflects our ...
UroToday3d
Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy
Purpose/objectives: Rectal spacers have been shown to reduce rectal side effects in patients receiving prostate radiation. However, concerns remain regarding precise and reproducible gel injection. We ...
UroToday3d
Positive Guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III Trial in Patients with Recurrence of Prostate Cancer
United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for 64Cu-SAR-bisPSMA diagnostic in prostate cancer patients with biochemical recurrence ...
UroToday3d
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the novel NAMPT Inhibitor OT-82.
Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is an inherited cancer syndrome caused by germline pathogenic variants in the fumarate hydratase (FH) gene. Affected individuals are at risk for ...
UroToday3d
"I Just Had to Do What I Had to Do": Characterizing Direct and Indirect Prostate Cancer Treatment Costs for Black Survivors and Their Caregivers.
Introduction. Financial hardship is prevalent among Black prostate cancer survivors and exacerbates health disparities. Characterizing and sharing cost information with patients can facilitate ...
UroToday3d
Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer.
To evaluate how prostate-specific antigen (PSA) levels decrease after removal of isolated prostate cancer (PCa) nodal metastases in relation to their diameter/volume ("PSA-density of PCa-metastases") ...